Skip to main content
. 2023 Dec 12;29(12):3050–3058. doi: 10.1038/s41591-023-02600-4

Extended Data Fig. 4.

Extended Data Fig. 4

Cost-effectiveness outcomes assuming (A) 3% discount for both costs and effects; (B) using life-years without disability weights; (C) assuming low screening adherence; and (D) assuming favorable VIA performance; (E) including pre-cancer treatment disutilities for HALYs calculation. *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV16/18 positive women treated after assessment of eligibility for ablative treatment; women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA.